Role of extracellular vesicles in liver diseases and their therapeutic potential
[Display omitted] •Injured cells release pathological extracellular vesicles (EVs).•Pathological EVs contain miRNAs, proteins, phospholipids and DNA.•Targeting EV release or use of bioengineered EVs represent therapeutic strategies. More than eight hundred million people worldwide have chronic liver...
Gespeichert in:
| Veröffentlicht in: | Advanced drug delivery reviews 2021-08, Vol.175, p.113816-113816, Article 113816 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 113816 |
|---|---|
| container_issue | |
| container_start_page | 113816 |
| container_title | Advanced drug delivery reviews |
| container_volume | 175 |
| creator | Kostallari, Enis Valainathan, Shantha Biquard, Louise Shah, Vijay H. Rautou, Pierre-Emmanuel |
| description | [Display omitted]
•Injured cells release pathological extracellular vesicles (EVs).•Pathological EVs contain miRNAs, proteins, phospholipids and DNA.•Targeting EV release or use of bioengineered EVs represent therapeutic strategies.
More than eight hundred million people worldwide have chronic liver disease, with two million deaths per year. Recurring liver injury results in fibrogenesis, progressing towards cirrhosis, for which there doesn’t exists any cure except liver transplantation. Better understanding of the mechanisms leading to cirrhosis and its complications is needed to develop effective therapies. Extracellular vesicles (EVs) are released by cells and are important for cell-to-cell communication. EVs have been reported to be involved in homeostasis maintenance, as well as in liver diseases. In this review, we present current knowledge on the role of EVs in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, alcohol-associated liver disease, chronic viral hepatitis, primary liver cancers, acute liver injury and liver regeneration. Moreover, therapeutic strategies involving EVs as targets or as tools to treat liver diseases are summarized. |
| doi_str_mv | 10.1016/j.addr.2021.05.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2537630157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X21001903</els_id><sourcerecordid>2537630157</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-e6f0a28829a9894580e0182e3d2b605bd41d763ef95290151786ac878217921a3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gAfZo5ddJ9mvBLxI8QsKiih4C2kyiynb3Zpki_57s7R69DKB4XlfJg8h5xQyCrS6WmXKGJcxYDSDMgNWHZAp5TVLORPFIZlGSKQFiPcJOfF-BUBZXcExmeQF8DpnYkqeX_oWk75J8Cs4pbFth1a5ZIve6hZ9YruktVt0ibEelY8b1ZkkfKB143Rqg0OwOtn0AbtgVXtKjhrVejzbvzPydnf7On9IF0_3j_ObRaqLQoQUqwYU4_FQJbgoSg4IlDPMDVtWUC5NQU1d5diIkgmgJa15pTSvOaO1YFTlM3K56924_nNAH-Ta-vF-1WE_eMnKPOZjso4o26Ha9d47bOTG2bVy35KCHE3KlRxNytGkhFJGkzF0se8flms0f5FfdRG43gEYf7m16KTXFjuNxjrUQZre_tf_Ax8_g8o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2537630157</pqid></control><display><type>article</type><title>Role of extracellular vesicles in liver diseases and their therapeutic potential</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kostallari, Enis ; Valainathan, Shantha ; Biquard, Louise ; Shah, Vijay H. ; Rautou, Pierre-Emmanuel</creator><creatorcontrib>Kostallari, Enis ; Valainathan, Shantha ; Biquard, Louise ; Shah, Vijay H. ; Rautou, Pierre-Emmanuel</creatorcontrib><description>[Display omitted]
•Injured cells release pathological extracellular vesicles (EVs).•Pathological EVs contain miRNAs, proteins, phospholipids and DNA.•Targeting EV release or use of bioengineered EVs represent therapeutic strategies.
More than eight hundred million people worldwide have chronic liver disease, with two million deaths per year. Recurring liver injury results in fibrogenesis, progressing towards cirrhosis, for which there doesn’t exists any cure except liver transplantation. Better understanding of the mechanisms leading to cirrhosis and its complications is needed to develop effective therapies. Extracellular vesicles (EVs) are released by cells and are important for cell-to-cell communication. EVs have been reported to be involved in homeostasis maintenance, as well as in liver diseases. In this review, we present current knowledge on the role of EVs in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, alcohol-associated liver disease, chronic viral hepatitis, primary liver cancers, acute liver injury and liver regeneration. Moreover, therapeutic strategies involving EVs as targets or as tools to treat liver diseases are summarized.</description><identifier>ISSN: 0169-409X</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2021.05.026</identifier><identifier>PMID: 34087329</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Cholestasis - drug therapy ; Cholestasis - pathology ; Cirrhosis ; Exosomes ; Extracellular Vesicles - drug effects ; Extracellular Vesicles - pathology ; Fibrosis ; Hepatitis, Viral, Human - drug therapy ; Hepatitis, Viral, Human - pathology ; Humans ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - pathology ; Liver Diseases - drug therapy ; Liver Diseases - pathology ; Liver Diseases, Alcoholic - drug therapy ; Liver Diseases, Alcoholic - pathology ; Microvesicles ; Portal hypertension ; Steatosis</subject><ispartof>Advanced drug delivery reviews, 2021-08, Vol.175, p.113816-113816, Article 113816</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-e6f0a28829a9894580e0182e3d2b605bd41d763ef95290151786ac878217921a3</citedby><cites>FETCH-LOGICAL-c449t-e6f0a28829a9894580e0182e3d2b605bd41d763ef95290151786ac878217921a3</cites><orcidid>0000-0002-9980-2104 ; 0000-0002-1356-6543 ; 0000-0001-9567-1859</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169409X21001903$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34087329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kostallari, Enis</creatorcontrib><creatorcontrib>Valainathan, Shantha</creatorcontrib><creatorcontrib>Biquard, Louise</creatorcontrib><creatorcontrib>Shah, Vijay H.</creatorcontrib><creatorcontrib>Rautou, Pierre-Emmanuel</creatorcontrib><title>Role of extracellular vesicles in liver diseases and their therapeutic potential</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>[Display omitted]
•Injured cells release pathological extracellular vesicles (EVs).•Pathological EVs contain miRNAs, proteins, phospholipids and DNA.•Targeting EV release or use of bioengineered EVs represent therapeutic strategies.
More than eight hundred million people worldwide have chronic liver disease, with two million deaths per year. Recurring liver injury results in fibrogenesis, progressing towards cirrhosis, for which there doesn’t exists any cure except liver transplantation. Better understanding of the mechanisms leading to cirrhosis and its complications is needed to develop effective therapies. Extracellular vesicles (EVs) are released by cells and are important for cell-to-cell communication. EVs have been reported to be involved in homeostasis maintenance, as well as in liver diseases. In this review, we present current knowledge on the role of EVs in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, alcohol-associated liver disease, chronic viral hepatitis, primary liver cancers, acute liver injury and liver regeneration. Moreover, therapeutic strategies involving EVs as targets or as tools to treat liver diseases are summarized.</description><subject>Animals</subject><subject>Cholestasis - drug therapy</subject><subject>Cholestasis - pathology</subject><subject>Cirrhosis</subject><subject>Exosomes</subject><subject>Extracellular Vesicles - drug effects</subject><subject>Extracellular Vesicles - pathology</subject><subject>Fibrosis</subject><subject>Hepatitis, Viral, Human - drug therapy</subject><subject>Hepatitis, Viral, Human - pathology</subject><subject>Humans</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Diseases - drug therapy</subject><subject>Liver Diseases - pathology</subject><subject>Liver Diseases, Alcoholic - drug therapy</subject><subject>Liver Diseases, Alcoholic - pathology</subject><subject>Microvesicles</subject><subject>Portal hypertension</subject><subject>Steatosis</subject><issn>0169-409X</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlb_gAfZo5ddJ9mvBLxI8QsKiih4C2kyiynb3Zpki_57s7R69DKB4XlfJg8h5xQyCrS6WmXKGJcxYDSDMgNWHZAp5TVLORPFIZlGSKQFiPcJOfF-BUBZXcExmeQF8DpnYkqeX_oWk75J8Cs4pbFth1a5ZIve6hZ9YruktVt0ibEelY8b1ZkkfKB143Rqg0OwOtn0AbtgVXtKjhrVejzbvzPydnf7On9IF0_3j_ObRaqLQoQUqwYU4_FQJbgoSg4IlDPMDVtWUC5NQU1d5diIkgmgJa15pTSvOaO1YFTlM3K56924_nNAH-Ta-vF-1WE_eMnKPOZjso4o26Ha9d47bOTG2bVy35KCHE3KlRxNytGkhFJGkzF0se8flms0f5FfdRG43gEYf7m16KTXFjuNxjrUQZre_tf_Ax8_g8o</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Kostallari, Enis</creator><creator>Valainathan, Shantha</creator><creator>Biquard, Louise</creator><creator>Shah, Vijay H.</creator><creator>Rautou, Pierre-Emmanuel</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9980-2104</orcidid><orcidid>https://orcid.org/0000-0002-1356-6543</orcidid><orcidid>https://orcid.org/0000-0001-9567-1859</orcidid></search><sort><creationdate>20210801</creationdate><title>Role of extracellular vesicles in liver diseases and their therapeutic potential</title><author>Kostallari, Enis ; Valainathan, Shantha ; Biquard, Louise ; Shah, Vijay H. ; Rautou, Pierre-Emmanuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-e6f0a28829a9894580e0182e3d2b605bd41d763ef95290151786ac878217921a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Cholestasis - drug therapy</topic><topic>Cholestasis - pathology</topic><topic>Cirrhosis</topic><topic>Exosomes</topic><topic>Extracellular Vesicles - drug effects</topic><topic>Extracellular Vesicles - pathology</topic><topic>Fibrosis</topic><topic>Hepatitis, Viral, Human - drug therapy</topic><topic>Hepatitis, Viral, Human - pathology</topic><topic>Humans</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Diseases - drug therapy</topic><topic>Liver Diseases - pathology</topic><topic>Liver Diseases, Alcoholic - drug therapy</topic><topic>Liver Diseases, Alcoholic - pathology</topic><topic>Microvesicles</topic><topic>Portal hypertension</topic><topic>Steatosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kostallari, Enis</creatorcontrib><creatorcontrib>Valainathan, Shantha</creatorcontrib><creatorcontrib>Biquard, Louise</creatorcontrib><creatorcontrib>Shah, Vijay H.</creatorcontrib><creatorcontrib>Rautou, Pierre-Emmanuel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kostallari, Enis</au><au>Valainathan, Shantha</au><au>Biquard, Louise</au><au>Shah, Vijay H.</au><au>Rautou, Pierre-Emmanuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of extracellular vesicles in liver diseases and their therapeutic potential</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>175</volume><spage>113816</spage><epage>113816</epage><pages>113816-113816</pages><artnum>113816</artnum><issn>0169-409X</issn><eissn>1872-8294</eissn><abstract>[Display omitted]
•Injured cells release pathological extracellular vesicles (EVs).•Pathological EVs contain miRNAs, proteins, phospholipids and DNA.•Targeting EV release or use of bioengineered EVs represent therapeutic strategies.
More than eight hundred million people worldwide have chronic liver disease, with two million deaths per year. Recurring liver injury results in fibrogenesis, progressing towards cirrhosis, for which there doesn’t exists any cure except liver transplantation. Better understanding of the mechanisms leading to cirrhosis and its complications is needed to develop effective therapies. Extracellular vesicles (EVs) are released by cells and are important for cell-to-cell communication. EVs have been reported to be involved in homeostasis maintenance, as well as in liver diseases. In this review, we present current knowledge on the role of EVs in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, alcohol-associated liver disease, chronic viral hepatitis, primary liver cancers, acute liver injury and liver regeneration. Moreover, therapeutic strategies involving EVs as targets or as tools to treat liver diseases are summarized.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34087329</pmid><doi>10.1016/j.addr.2021.05.026</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9980-2104</orcidid><orcidid>https://orcid.org/0000-0002-1356-6543</orcidid><orcidid>https://orcid.org/0000-0001-9567-1859</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-409X |
| ispartof | Advanced drug delivery reviews, 2021-08, Vol.175, p.113816-113816, Article 113816 |
| issn | 0169-409X 1872-8294 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2537630157 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Cholestasis - drug therapy Cholestasis - pathology Cirrhosis Exosomes Extracellular Vesicles - drug effects Extracellular Vesicles - pathology Fibrosis Hepatitis, Viral, Human - drug therapy Hepatitis, Viral, Human - pathology Humans Liver Cirrhosis - drug therapy Liver Cirrhosis - pathology Liver Diseases - drug therapy Liver Diseases - pathology Liver Diseases, Alcoholic - drug therapy Liver Diseases, Alcoholic - pathology Microvesicles Portal hypertension Steatosis |
| title | Role of extracellular vesicles in liver diseases and their therapeutic potential |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A36%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20extracellular%20vesicles%20in%20liver%20diseases%20and%20their%20therapeutic%20potential&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Kostallari,%20Enis&rft.date=2021-08-01&rft.volume=175&rft.spage=113816&rft.epage=113816&rft.pages=113816-113816&rft.artnum=113816&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2021.05.026&rft_dat=%3Cproquest_cross%3E2537630157%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2537630157&rft_id=info:pmid/34087329&rft_els_id=S0169409X21001903&rfr_iscdi=true |